ArticleJACC. CardioOncology2025
Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction.
Abstract read
In one paragraph
Article in JACC. CardioOncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Triple-M syndrome after immune checkpoint inhibitors: a systematic review of cases-early recognition is critical to survival.Frontiers in neurology · 2026Pooled it
- Circulating Biomarkers in Cardio-Oncology: Prediction and Prognostication.Current cardiology reports · 2026Review
- Triple M Overlap Syndrome After Immune Checkpoint Inhibitors: A Case Series of a High-Mortality Phenotype.JACC. Case reports · 2026Article
- Atherosclerotic Cardiovascular Disease and Cancer.Immunological reviews · 2026Review
- Development and external validation of a multivariable nomogram for predicting severe immune checkpoint inhibitor-associated myocarditis in advanced lung cancer.Translational lung cancer research · 2026Article
- Triple M overlap syndrome in the intensive care unit: differential diagnosis and management.Critical care (London, England) · 2026Review
- Multimodality Imaging in Myocarditis: Integrating Etiology, Diagnosis, and Risk Stratification.Current cardiology reports · 2026Review
- Global epidemiology of myocarditis: disparities in age, sex and geography.Nature reviews. Cardiology · 2026Review
- Recovery from fulminant immune-related myocarditis induced by ipilimumab plus nivolumab in malignant pleural mesothelioma: a case report.BMC pulmonary medicine · 2026Article
- Immune Checkpoint Inhibitor-Associated Myocarditis: Risk, Diagnosis, and Clinical Impact.Journal of clinical medicine · 2026Review
- Research Priorities and Future Directions in Cardio-Oncology.Current treatment options in oncology · 2026Review
- Advancing precision cardio-oncology: multimodal surveillance and stratified management of immunotherapy-induced cardiovascular toxicity.Frontiers in cardiovascular medicine · 2026Review
- Cardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor-Myocarditis: Diagnostic and Prognostic Evidence and Limitations.Current heart failure reports · 2025Review
- Prognostic risk factors and a survival prediction model for immune checkpoint inhibitor related myocarditis in patients with lung cancer: a multicenter study.Scientific reports · 2025Observational
- Immune checkpoint inhibitor-related myocarditis: a comprehensive analysis of clinical manifestations and prognostic factors.The oncologist · 2025Article
- Outcomes and Predictors of Severity of Immunotherapy-Related Myocarditis.JACC. CardioOncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
57 authors.
Yen-Chou ChenDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA; Division of Cardiology and Cardiovascular Research Center, Taipei Medical University Hospital, Taipei, Taiwan; Taipei Heart Institute, Taipei Medical University, Taipei, Taiwan. Electronic address: yenchou135@gmail.com.
Charles DolladilleNormandie Université, UNICAEN, INSERM U1086 ANTICIPE, Caen, France; Caen-Normandy University Hospital, PICARO Cardio-Oncology Program, Department of Pharmacology, Caen, France; Department of Pharmacology, Sorbonne University, INSERM, CIC-1901, Hôpital Pitié-Salpétrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
Anjali RaoDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA; Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Nicolas L PalaskasDepartment of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Anita DeswalDepartment of Cardiology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Lorenz LehmannDepartment of Cardiology, Angiology, and Pneumology, University Hospital of Heidelberg, Heidelberg, Germany; German Centre for Cardiovascular Research, partner site Heidelberg/Mannheim, Mannheim, Germany; German Cancer Research Center, Heidelberg, Germany.
Jennifer CautelaDepartment of Cardiology, University Mediterranean Centre of CardioOncology, Nord Hospital, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, INSERM, INRAE, C2VN, Marseille, France.
Pierre-Yves CourandFédération de Cardiologie, Hôpital de la Croix-Rousse et Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France; Université de Lyon, Université Claude Bernard, Lyon, France.
Salim HayekDepartment of Cardiology, University of Michigan, Ann Arbor, Michigan, USA.
Han ZhuDivision of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California, USA.
Richard K ChengDivision of Cardiology, University of Washington, Seattle, Washington, USA.
Joachim AlexandreNormandie Université, UNICAEN, INSERM U1086 ANTICIPE, Caen, France; Caen-Normandy University Hospital, PICARO Cardio-Oncology Program, Department of Pharmacology, Caen, France.
Lauren A BaldassarreDepartment of Cardiology, Yale University, New Haven, Connecticut, USA.
François RoubilleDepartment of Cardiology, INI-CRT, CHU de Montpellier, PhyMedExp, Université de Montpellier, Inserm, CNRS, Montpellier, France.
Michal Laufer-PerlDepartment of Cardiology, Tel Aviv Sourasky Medical Center, affiliated to the Tel Aviv University Faculty of Medicine, Tel Aviv-Yafo, Israel.
Aarti AsnaniDivision of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Stephane EderhyCardiology Department, Hospital Saint Antoine, Assistance Publique-Hôpitaux de Paris, Paris, France.
Yuichi TamuraCardiovascular Center, International University of Health and Welfare, Mita Hospital, Tokyo, Japan.
Sanjeev FrancisCardiovascular Service Line, Maine Medical Center, Portland, Maine, USA.
Elizabeth M GaughanDivision of Hematology and Oncology, University of Virginia, Charlottesville, Virginia, USA.
Douglas B JohnsonDivision of Hematology and Oncology, Vanderbilt University, Nashville, Tennessee, USA.
Danette L FlintHeart and Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Peter P RainerDivision of Cardiology, Medical University of Graz, Graz Austria; BioTechMed Graz, Graz, Austria; St. Johann in Tirol General Hospital, St. Johann in Tirol, Austria.
Guillaume BaillyAssistance Publique-Hôpitaux de Paris Hôpital Lariboisière, Paris, France.
Steven M EwerDivision of Cardiovascular Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Mandar A ArasDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Dimitri ArangalageDepartment of Cardiology, Bichat Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Université de Paris, UMRS1148, INSERM, Paris, France; Université de Paris, Paris, France.
Eve CariouDepartment of Cardiology, Rangueil University Hospital, Toulouse, France.
Roberta FloridoDivision of Cardiology, Johns Hopkins University, Baltimore, Maryland, USA.
Giovanni PerettoDisease Unit for Myocarditis and Arrhythmogenic Cardiomyopathies, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Osnat Itzhaki Ben ZadokCardiology Department, Rabin Medical Center, Petah-Tikva, Israel.
Nausheen AkhterDivision of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
Anna NarezkinaDivision of Cardiovascular Medicine, University of California-San Diego, San Diego, California, USA.
Joshua E LevensonHeart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Yan LiuDivision of Cardiology, Department of Internal Medicine, Dell Medical School, University of Texas at Austin, Austin, Texas, USA.
Shanthini M CruszBarts Health NHS Trust, University College London Hospital, London, United Kingdom.
Nahema IssaBordeaux University Hospital, Bordeaux, France.
Nicolas PiriouNantes Univesrité, CHU Nantes, Centre de Reference Cardiomyopathies, l'Institut du Thorax, Nantes, France.
Darryl LeongDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.
Shahneen SandhuDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia.
Isik TurkerDepartment of Cardiology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.
Pedro MolinerBellvitge University Hospital, Catalan Institute of Oncology, Cardiology Department, Bio-Heart Cardiovascular Diseases Research Group, Bellvitge Biomedical Research Institute, CIBER CV, l'Hospitalet de Llobregat, Barcelona, Spain.
Michel ObeidCentre Hospitalier Universitaire Vaudois, University of Lausanne, LCIT Center, Immunology and Allergy Service, Lausanne, Switzerland.
Lucie HeinzerlingDepartment of Dermatology and Allergy, University Hospital, LMU Munich, Germany.
Wei-Ting ChangChi Mei Medical Center, Tainan, Taiwan.
Andrew StewartDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Vishnu VenkateshDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Zoe DuUniversity of Texas at Dallas, Dallas, Texas, USA.
Anirudh YadavalliUniversity of Texas at Dallas, Dallas, Texas, USA.
Dohyeong KimUniversity of Texas at Dallas, Dallas, Texas, USA.
Alvin ChandraDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Kathleen W ZhangDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
John R PowerDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California.
Javid MoslehiDivision of Cardiology, University of California-San Francisco, San Francisco, California, USA.
Joe-Elie SalemDepartment of Pharmacology, Sorbonne University, INSERM, CIC-1901, Hôpital Pitié-Salpétrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
Vlad G ZahaDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. Electronic address: vlad.zaha@utsouthwestern.edu.
International ICI Myocarditis Registry
Funding
Investigating CXCR3 Blockade as Precision Therapy for Cardiac Sarcoidosis using Single-Cell Multi-omics and TCR PhenotypingR01HL174432 · NHLBI · STANFORD UNIVERSITY · PI Han Zhu · 2024 to 2026
$2.2MIdentification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced MyocarditisK08HL161405 · NHLBI · STANFORD UNIVERSITY · PI Han Zhu · 2022 to 2026
$880kCXCL9/10 Macrophage Induced CXCR3+ T-cell Recruitment to the Heart Contributes to Immunotherapy MyocarditisR03HL173146 · NHLBI · STANFORD UNIVERSITY · PI ZHU, HAN · 2024 to 2025
$236kNHLBI NIH HHS K08 HL161405NHLBI NIH HHS R01 HL174432NHLBI NIH HHS R03 HL173146
Abstract
backgroundImmune checkpoint inhibitors (ICIs) have transformed cancer treatment, but ICI myocarditis (ICI-M) remains a potentially fatal complication. The clinical implications and predictors of left ventricular ejection fraction (LVEF) <50% in ICI-M are not well understood.
objectivesThe aim of this study was to identify factors associated with LVEF <50% vs ≥50% at the time of hospitalization for ICI-M. A secondary objective was to evaluate the relationship between LVEF and 30-day all-cause mortality.
methodsThe International ICI-Myocarditis Registry, a retrospective, international, multicenter database, included 757 patients hospitalized with ICI-M. Patients were stratified by LVEF as reduced LVEF (<50%) or preserved LVEF (≥50%) on admission. Cox proportional hazards models were used to assess the associations between LVEF and clinical events, and multivariable logistic regression was conducted to examine factors linked to LVEF.
resultsOf 757 patients, 707 had documented LVEFs on admission: 244 (35%) with LVEF <50% and 463 (65%) with LVEF ≥50%. Compared with patients with LVEF ≥50%, those with LVEF <50% were younger (<70 years), had a body mass index of <25 kg/m
conclusionsDyspnea, time from ICI initiation, a history of heart failure, and prior cardiotoxic therapy may be predictors of an initial LVEF <50% in patients with ICI-M.
Indexed as
cardiac magnetic resonanceechocardiographyheart failureimmune checkpoint inhibitor myocarditisimmunotherapyleft ventricular ejection fractionmyocarditistroponin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.